Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

Summary

The primary goal of this study is to gather efficacy data concerning the progression-free survival rate with electromagnetic fields plus Regorafenib when compared to historical data with Regorafenib alone as a second-line therapy in patients with advanced hepatocellular carcinoma who have received any first line systemic therapy either standard of care Sorafenib or Lenvatinib or any experimental therapy. Patients who have received any treatment that includes either electromagnetic fields or Regorafenib will be excluded.

Timeline

Start

2021-01-26

Primary completion

2024-05-31

Completion

2024-05-31

Drugs

Indications